105 related articles for article (PubMed ID: 31837958)
1. Alisertib: a new option for acute myeloid leukaemia.
Thomas X
Lancet Haematol; 2020 Feb; 7(2):e87-e88. PubMed ID: 31837958
[No Abstract] [Full Text] [Related]
2. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma.
Cohen JB; Maddocks KJ; Huang Y; Christian BA; Jaglowski SM; Flowers CR; Blum KA
Leuk Lymphoma; 2017 Sep; 58(9):1-2. PubMed ID: 28278718
[No Abstract] [Full Text] [Related]
3. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
[TBL] [Abstract][Full Text] [Related]
7. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator's Choice (LUMIERE trial; NCT01482962).
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27007010
[No Abstract] [Full Text] [Related]
8. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
[TBL] [Abstract][Full Text] [Related]
9. First Multicenter, Randomized Phase 3 Study in Patients (Pts) With Relapsed/Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL): Alisertib (MLN8237) Versus Investigator’s Choice (LUMIERE trial; NCT01482962).
Clin Adv Hematol Oncol; 2016 Feb; 14(2 Suppl 1):12-3. PubMed ID: 27466629
[No Abstract] [Full Text] [Related]
10. Ibrutinib is an effective treatment for B-cell prolymphocytic leukaemia.
Gordon MJ; Raess PW; Young K; Spurgeon SEF; Danilov AV
Br J Haematol; 2017 Nov; 179(3):501-503. PubMed ID: 27391978
[No Abstract] [Full Text] [Related]
11. Idasanutlin as a new treatment option in improving the therapeutic odyssey of relapsed/refractory AML.
Corbali MO; Eskazan AE
Future Oncol; 2020 May; 16(14):887-889. PubMed ID: 32338053
[No Abstract] [Full Text] [Related]
12. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
[TBL] [Abstract][Full Text] [Related]
13. First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE; Ayer M; Kantarcioglu B; Arica D; Demirel N; Aydin D; Yalniz FF; Elverdi T; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Br J Haematol; 2014 Oct; 167(1):139-41. PubMed ID: 24815307
[No Abstract] [Full Text] [Related]
14. Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure.
Sonmez M; Cobanoglu U; Ovali E; Omay SB
J Clin Pharm Ther; 2008 Jun; 33(3):329-30. PubMed ID: 18452422
[No Abstract] [Full Text] [Related]
15. Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors.
Liewer S; Huddleston A
Expert Opin Investig Drugs; 2018 Jan; 27(1):105-112. PubMed ID: 29260599
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
[TBL] [Abstract][Full Text] [Related]
17. Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships.
Venkatakrishnan K; Zhou X; Ecsedy J; Mould DR; Liu H; Danaee H; Fingert H; Kleinfield R; Milton A
J Clin Pharmacol; 2015 Mar; 55(3):336-47. PubMed ID: 25302940
[TBL] [Abstract][Full Text] [Related]
18. Midostaurin in FLT3-mutated acute myeloid leukaemia.
Das M
Lancet Oncol; 2017 Aug; 18(8):e439. PubMed ID: 28669736
[No Abstract] [Full Text] [Related]
19. A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.
Rosenthal A; Kumar S; Hofmeister C; Laubach J; Vij R; Dueck A; Gano K; Stewart AK
Br J Haematol; 2016 Jul; 174(2):323-5. PubMed ID: 26403323
[No Abstract] [Full Text] [Related]
20. Existing and emerging therapeutic options for the treatment of acute myeloid leukemia.
Tallman M
Clin Adv Hematol Oncol; 2008 Nov; 6(11):3-5. PubMed ID: 19205108
[No Abstract] [Full Text] [Related]
[Next] [New Search]